The Food and Drug Administration (FDA) is scheduled to approve a new COVID-19 booster aimed at fighting both the original strain and the Omicron variant
Although Americans have watched as both Moderna and Pfizer made billions off of a drug that didn't stop the pandemic, it seems the new booster will be approved with human trials not being finished
According to a report conducted by the Wall Street Journal, the vaccine will be bivalent, meaning it can fight both the OMICRON and the original COVID strains.
https://www.lifezette.com/2022/08/fda-set-to-authorize-testing-booster-on-the-general-public-without-human-trial-data/?utm_source=home-top-stories
No comments:
Post a Comment